In recent years, CAR-T cell therapy has proven to be a promising approach 25 against cancer. Nonetheless, this approach still faces multiple challenges in 26 eliminating solid tumors, one of which being the immunosuppressive tumor 27 microenvironment (TME). Here we demonstrated that knocking out the endogenous 28 TGFβ receptor II (TGFBR2) in CAR-T cells with CRISPR/Cas9 technology could 29 reduce the induced regulatory T-cell (iTreg) conversion and prevent the exhaustion of 30 CAR-T cells. Meanwhile, TGFBR2 edited CAR-T cells had better in vivo tumor 31 elimination efficacy, both in cell line derived xenograft (CDX) and patient derived 32 xenograft (PDX) solid tumor models, whether administered locally or systemically. In 33 addition, the TGFBR2 edited CAR-T cells could eliminate contralaterally re-34 inoculated xenografts in mice effectively with an increased proportion of central 35 memory and effector memory subsets. In conclusion, we greatly improved the in vitro 36 and in vivo function of CAR-T cells in TGFβ-rich tumor environments by knocking 37 out endogenous TGFBR2, proposing a new method to improve the efficacy of CAR-T 38 cell therapy for treating solid tumors.
suggesting TGFβ1 induces CAR-T cell exhaustion. With TGFBR2 removed, the 141 TGFβ1 effects on the expression of above-mentioned genes were largely abolished 142 (Figures 2A, 2B , and S4, 4T vs. 4T+T, 8T vs. 8T+T). We further confirmed the 143 TGFβ1-induced expression changes of these genes by qPCR ( Figures 2C and 2D) . 144 Therefore, we focused on the TGFβ1-induced iTreg phenotype and CAR-T cell 145 exhaustion in the following experiments. Figure 3C ).
171
These results suggest that the inhibition of TGFβ1-FOXP3 signal improves 172 CAR-T cell function by reducing iTreg-like cell conversion. However, this pathway is 173 only partially responsible for the negative effects of TGFβ1 on CAR-T cell function. Figure S7 ). It is worth noting that among these markers,
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PD1 was one of the most upregulated and there were still a considerable number of 194 cells expressing PD1 in M28z-TKO cells, indicating that although they were 195 unresponsive to TGFβ1 signaling, they were still prone to PD1 suppression, as 196 engaged by corresponding ligands in the TME. Figure 4F ). In the presence of TGFβ1 and PDL1 over-205 expression, the tumor lysis capability of M28z was reduced at round 2 and completely 206 lost at round 3. M28z-PKO was able to achieve over 90% tumor lysis at round 3, and 207 lost efficacy at round 4. In contrast, M28z-TKO was able to maintain about 60% 208 tumor lysis capability at round 4 ( Figure 4G ). All these data showed that PD1 up-209 regulation partially contributed to the negative regulation effect of TGFβ. On the 210 other hand, TGFβ signaling was only partially responsible for PD1 expression, as a 211 portion of TKO cells can still express PD1, therefore subjected to PDL1 suppression. The DKO CAR-T cells had the best performance, eliminating about 90% of tumor at 213 round 4 ( Figure 4G ), suggesting that simultaneous blocking both TGFβ and PD1 214 signaling can further improve the CAR-T's resistance to suppressive TME. Figure 5A ). We suspected that these TGFβ1 in TME 223 was partially released by the mouse stromal cells. To confirm the effect of mouse 224 TGFβ1, we added it to human CAR-T cells, and observed an inhibitory effect similar 225 to human TGFβ1 ( Figure S8 ).
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After the tumor reached a defined size (200-300 mm 3 ), we performed intra- Figure 6C ). At day 75 after treatment, we terminated the experiments 258 and harvested the tumors for analysis. Using RNAscope technology, we found that 259 the number of tumor-infiltrating M28z-TKO cells was much higher than M28z cells 260 ( Figure 6D) , and a significant portion of these M28z-TKO CAR-T cells were 261 functional and proliferating as they were IFNG or KI67 positive ( Figure 6E ). These As the tumor microenvironment usually contains multiple inhibitory signals, we 266 further challenged M28z-TKO CAR-T cells with a more suppressive TME. We over-267 expressed PDL1 in CRL5826 cells, generated a CRL5826-PDL1 CDX model, and (Figures 8E and S11B) . The proportion of hCD3 and GFP positive 302 cells remained around 20%-40% in peripheral circulation of these mice ( Figure 8F ). T 303 cell subset analysis showed that effector memory and central memory cells still 304 accounted for the majority of hCD3 positive cells in M28z-TKO group (Figure 8G ).
305
The body weights of mice in M28z-TKO treated group were lighter (Figures S11C 306 and S11D), suggesting GvHD caused by enhanced T cell proliferation during first and 307 second xenograft challenges.
308
Considering the antigens recognized by CAR-T cells are usually only expressed 309 in partial primary tumor cells, we established another PDX model of pancreatic 310 carcinoma, which has a weaker and more heterogenous expression of mesothelin and 311 a more compact structure ( Figure 9A ). With only some of the tumor cells expressing (Figures 9C and 9D) . In contrast to the first PDX model, in this 319 experiment, no mice showed severe weight lost or any GvHD phenotype during the 320 initial treatment or the re-inoculation of tumor ( Figure S12A ). We examined the 321 peripheral blood of mice at day 34 after initial injection and day 22 after re-322 inoculation of tumor, the percentage of hCD3 positive cells were around 5% (Figures 323 S12C and S12D). These results suggest that the PDX tumor 2 does not induce CAR-T 324 cell proliferation as efficiently as PDX tumor 1, likely due to its lower and 325 13 13 heterogenous mesothelin expression and more concrete structure. However, even with 326 less circulating cells, M28z-TKO cells can still efficiently eradicate the tumor, even 327 after a second inoculation, indicating a potent and lasting anti-tumor effect. Figure S13 ).
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One of the main reasons for the poor clinical efficacy of CAR-T cells in treating 340 solid tumor is the lack of robust in vivo proliferation (34) (35) (36) (37) . In this study, we 341 demonstrated that, knocking out TGFBR2 enables CAR-T cells to survive and 342 proliferate better in tumor xenograft mouse models, leading to significantly improved promising strategy to improve the proliferation of CAR-T cells when treating solid 354 tumor patients.
355
Considering the clinical therapeutic effect of CAR-T cells is likely affected by 356 the histopathologic type, and the heterogeneity of TAA expression in solid tumor(37, 357 38), we established two PDX models using different pancreatic carcinoma samples to 358 evaluate the function of TGFBR2 KO CAR-T cells. We observed that these two 359 xenografts, regardless of loose or compact structure, all or partial expression of target 360 antigen, were both eradicated efficiently by TGFBR2 KO CAR-T cells, and the 361 residual edited CAR-T cells could eliminate the re-inoculated xenografts effectively.
362
These results suggest that TGFBR2 edited CAR-T cells function effectively in 363 different primary tumor environments. However, we also want to point out that TGFβ 364 signals through many cell types at TME to induce T cell suppression, and our CDX 365 and PDX models were only recapitulating some aspects of the TME. It is possible that 366 the lack of TGFβR II on T cells will allow for greater signaling through other cell 367 subsets, which is an important issue to be addressed using more sophisticated tumor 368 models.
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In the complex suppressive TME, different inhibitory cells and molecules inhibit 370 T cell function via multiple pathways (9). In the CRL5826 CDX model, which weakly 371 expressed PDL1 and was enriched for TGFβ1, CAR-T cells that had TGFβ signaling 372 inhibited via gene editing eradicated the tumors much more efficiently. In 373 comparison, in a TME highly expressing PDL1 (CRL5826-PDL1 CDX model), 374 although TGFBR2 edited CAR-T cells had the tumor eradicating advantage compared 375 to the unedited cells, they were not able to eradicate tumor in most mice, indicating 376 blocking only one inhibitory pathway was not enough to render the CAR-T cells 377 resistant to complex TME. When both PD1 and TGFβ pathways were blocked by 378 PDCD1-TGFBR2 double knockout, CAR-T cells were able to clear the tumor from 379 four out of five mice. These observations highlight the fact that inhibiting pathways 380 specific to particular TME could improve CAR-T cell function treating solid tumors, 
